

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6565275

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	YOO YOUNG PHARM CO., LTD.	02/16/2021
RECEIVING PARTY DATA		
Name:	CELLABMED INC.	
Street Address:	#1301-1, 38-21, DIGITAL-RO 31-GIL, GURO-GU	
City:	SEOUL	
State/Country:	KOREA, REPUBLIC OF	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15750453
CORRESPONDENCE DATA		
Fax Number:	(314)726-7501	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	314-726-7500	
Email:	kslefile@hdp.com	
Correspondent Name:	HARNESS, DICKEY AND PIERCE, PLC.	
Address Line 1:	7700 BONHOMME AVENUE, SUITE 400	
Address Line 4:	ST. LOUIS, MISSOURI 63105	
ATTORNEY DOCKET NUMBER:	16425-000018-US-NP	
NAME OF SUBMITTER:	KISUK LEE	
SIGNATURE:	/Kisuk Lee/	
DATE SIGNED:	02/23/2021	
Total Attachments: 2		
source=000018usnp_Assignment_CorpToCorp_Revised#page1.tif		
source=000018usnp_Assignment_CorpToCorp_Revised#page2.tif		

ASSIGNMENT

WHEREAS, **YOO YOUNG PHARM. CO., LTD.**, 33, Yongso 2-gil, Gwanghyewon-myeon, Jincheon-gun, Chungcheongbuk-do 27809 Republic of Korea (hereinafter "Assignor") owns all right, title and interest in:

- U.S. Patent Application No. 15/750,453, filed on February 5, 2018, titled, "CHIMERIC ANTIGEN RECEPTORS, AND T CELLS IN WHICH CHIMERIC ANTIGEN RECEPTOR IS EXPRESSED".

WHEREAS, **CellabMED Inc.**, #1301-1, 38-21, Digital-ro 31-gil, Guro-gu, Seoul, Republic of Korea (hereinafter "Assignee") is desirous of acquiring all right, title, and interest therein:

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy whereof is hereby acknowledged, Assignor hereby confirms any prior assignment to Assignee, and to the extent that Assignor has not already done so, agrees to assign, and hereby does, sell, assign and transfer unto Assignee and its successors in interest, the full and exclusive right, title and interest in the United States of America and throughout the world, including the right to claim priority under the laws of the United States, the Paris Convention, and any foreign countries, to the inventions as described in each of the aforesaid applications, to each of the aforesaid applications themselves, and all divisions, continuations, continuations-in-part, or other applications claiming priority directly or indirectly from the aforesaid application(s), and any United States or foreign Letters Patent, utility model, or other similar rights which may be granted thereon, including reissues, reexaminations and extensions thereof, and all copyright rights throughout the world in the aforesaid applications and patents and the subject matter disclosed therein, these rights, title and interest to be held and enjoyed by Assignee to the full end of the term for which the Letters Patent, utility model, or other similar rights, are granted and any extensions thereof as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made, and the right to sue for, and recover for past infringements of, or liabilities for, any of the rights relating to any of the applications, patents, utility models, or other similar rights, resulting therefrom, and the copyright rights.

Assignor hereby covenants and agrees to execute all instruments or documents required or requested for the making and prosecution of any applications of any type for patent, utility model, or other similar rights, and for copyright, in the United States and in all foreign countries including, but not limited to, any provisional, continuation, continuation-in-part, divisional, renewal or substitute thereof, any derivation proceedings relating thereto, and as to Letters Patent any supplemental examination, derivation proceeding, opposition, post grant review, reissue, re-examination, inter partes review, or extension thereof, and for litigation regarding, or for the purpose of defending the validity of or protecting title to the said invention, the United States application for patent, or Letters Patent therefor, and to testify in support thereof, for the benefit of Assignee and its successors in interest without further or other compensation than that above set forth.

Assignor hereby covenants that no assignment, sale, license, agreement or encumbrance has been or will be entered into which would conflict with this Assignment. Assignor further

ASSIGNMENT

covenants not to challenge, or assist or participate in any third party challenge to, the assigned inventions, or any patent application or patent thereon, whether by litigation, post grant review, inter partes review, covered business method review, reexamination, or otherwise.


Assignor hereby requests the United States Patent and Trademark Office to issue the Letters Patent of the United States of America to Assignee, and requests that any official of any country or countries foreign to the United States, whose duty it is to issue or grant patents and applications as aforesaid, to issue the Letters Patent, Utility Model Registration or other similar right to Assignee.

The undersigned hereby grants the law firm of Harness, Dickey & Pierce, P.L.C. the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

YOO YOUNG PHARM. CO., LTD.


33, Yongso 2-gil, Gwanghyewon-myeon, Jincheon-gun, Chungcheongbuk-do 27809 Republic of Korea

February 16, 2021
Date


Signature


Printed Name: Woo Pyoung YOO

Title: President & CEO


Witness Signature

Jong Hyeok PARK
Printed Name

February 16, 2021
Date


Witness Signature

Hwa Jin KONG
Printed Name

February 16, 2021
Date